title: Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
abstract: BACKGROUND
  Enoxaparin use in PCI has been investigated, however its role in primary PCI is less known.
  
  
  OBJECTIVE
  To evaluate the role of combination IV + SC enoxaparin in primary PCI in STEMI.
  
  
  METHODS
  83 consecutive patients with STEMI who underwent primary PCI between January 1, 2005 and January 15, 2008 were included. Anticoagulation was based on our institution's STEMI protocol; either IV + SC enoxaparin, or IV unfractionated heparin (UFH). Clinical endpoints included MACE, bleeding and net adverse cardiac events (NACE).
  
  
  RESULTS
  45 patients received UFH and 37 received IV + SC enoxaparin. There was no difference in the rate of mortality, MACE, or NACE. There was a trend toward more TIMI major and GUSTO moderate and severe bleeding in the UFH group.
  
  
  CONCLUSIONS
  Application of IV + SC enoxaparin strategy for primary PCI in STEMI appears both safe and efficacious. A prospective randomized trial will be necessary to evaluate the safety and efficacy more thoroughly.
authors.affiliation: Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 07112, USA.
authors.forename: Sargis
authors.initials: S
authors.lastname: Khoobiar
authors.forename: Nicolai
authors.initials: N
authors.lastname: Mejevoi
authors.forename: Khalil
authors.initials: K
authors.lastname: Kaid
authors.forename: Catalin
authors.initials: C
authors.lastname: Boiangiu
authors.forename: Sampoornima
authors.initials: S
authors.lastname: Setty
authors.forename: Anjum
authors.initials: A
authors.lastname: Tanwir
authors.forename: Khaula
authors.initials: K
authors.lastname: Khalid
authors.forename: Marc
authors.initials: M
authors.lastname: Cohen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D010865:Pilot Projects; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006493:Heparin